Several generics firms targeting Novartis’s Entresto (sacubitril/valsartan) blockbuster combination treatment for heart failure have scored a victory over the originator in the latest chapter of US multi-district litigation proceedings.
A US district court in Delaware has ruled invalid US patent 8,101,659, covering combinations of Entresto’s two active ingredients, ahead...






